Finland· FI-REL-REL59065

SOTYKTU

A deucravacitinib product containing deucravacitinib, registered in Finland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 12 of our 19 countries.

ATC L04AF07

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedSOTYKTUATCL04AF07REGISTER NO.FI-REL-REL59065PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Deucravacitinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AF07 (deucravacitinib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Deucravacitinib · ATC L04AF07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deucravacitinib costs, country by country.

Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Deucravacitinib · price per daily dose (6 mg)

USD · FX 28 Sept 2026

  • FR France$22.97
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Deucravacitinib
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Finland (FI)
ATC code
L04AF07
ATC class
Deucravacitinib
Defined daily dose
6 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Deucravacitinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deucravacitinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sotyktu
  • Liechtenstein · Sotyktu
  • Norway · Sotyktu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/88d26f4d-53af-47f7-8629-40fd3fcdf4a4
GET /v1/drugs/88d26f4d-53af-47f7-8629-40fd3fcdf4a4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "6",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "mg",
  "strength": "6 mg",
  "atc_label": "deukravasitinibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/23/1718/001-008",
  "fimea_rel_id": "REL59065",
  "authorised_at": "2023-03-24"
}

See everything about deucravacitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.